Trial Profile

A Phase 1/2, First-in-Human, Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NUV 1511 (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Prostate cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Nuvation Bio

Most Recent Events

03 Nov 2025 According to Nuvation Bio media release, the company expects to provide an update from the by year end 2025.
07 May 2025 According to Nuvation Bio media release, the company expects to provide an update from the Phase 1/2 dose escalation study of NUV-1511 in 2H 2025.
14 Mar 2024 According to Nuvation Bio media release, first patient has been dosed in this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com